After NBIX’s 15% Climb in a Month, HALO Looks Like the Stronger Long-Term Play
Halozyme Therapeutics (HALO) offers superior revenue growth across key periods, better profitability, and relatively lower valuation vs Neurocrine Biosciences (NBIX), suggesting you may be better off investing in HALO
- HALO’s quarterly revenue growth was 40.8%, vs. NBIX’s 11.1%.
- In addition, its Last 12 Months revenue growth came in at 35.0%, ahead of NBIX’s 21.7%.
- HALO leads on profitability over both periods – LTM margin of 57.9% and 3-year average of 47.8%.
NBIX develops and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders, including VMAT2 and catechol-O-methyltransferase inhibitors for tardive dyskinesia and Parkinson’s disease. HALO biopharma platform developing ENHANZE drug delivery technology and therapies like Perjeta, RITUXAN HYCELA, and MabThera SC for non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Valuation & Performance Overview
| NBIX | HALO | Preferred | |
|---|---|---|---|
| Valuation | |||
| P/EBIT Ratio | 28.7 | 13.5 | HALO |
| Revenue Growth | |||
| Last Quarter | 11.1% | 40.8% | HALO |
| Last 12 Months | 21.7% | 35.0% | HALO |
| Last 3 Year Average | 26.0% | 35.5% | HALO |
| Operating Margins | |||
| Last 12 Months | 20.8% | 57.9% | HALO |
| Last 3 Year Average | 20.6% | 47.8% | HALO |
| Momentum | |||
| Last 3 Year Return | 35.4% | 83.7% | HALO |
Note: For “Last 3 Year Return” metric, preferred stock is one with higher returns unless the returns are too high (>300%) which creates risk of sell off.
See more revenue details: NBIX Revenue Comparison | HALO Revenue Comparison
See more margin details: NBIX Operating Income Comparison | HALO Operating Income Comparison
But do these numbers tell the full story? Read Buy or Sell HALO Stock to see if Halozyme Therapeutics’s edge holds up under the hood or if Neurocrine Biosciences still has cards to play (see Buy or Sell NBIX Stock).
That is one way to look at stocks. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure
Historical Market Performance
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | Avg | Best | |
|---|---|---|---|---|---|---|---|---|---|
| Returns | |||||||||
| NBIX Return | -11% | -11% | 40% | 10% | 4% | 6% | 30% | ||
| HALO Return | 141% | -6% | 42% | -35% | 29% | 59% | 313% | <=== | |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 11% | 101% | ||
| Monthly Win Rates [3] | |||||||||
| NBIX Win Rate | 33% | 58% | 67% | 50% | 58% | 57% | 54% | ||
| HALO Win Rate | 83% | 42% | 58% | 33% | 50% | 57% | 54% | ||
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 62% | 63% | <=== | |
| Max Drawdowns [4] | |||||||||
| NBIX Max Drawdown | -30% | -17% | -15% | -25% | -15% | -36% | -23% | ||
| HALO Max Drawdown | -22% | -25% | -20% | -47% | -9% | -0% | -21% | ||
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | -12% | <=== | |
[1] Cumulative total returns since the beginning of 2020
[2] 2025 data is for the year up to 9/9/2025 (YTD)
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
No matter how good the numbers, stock investment is never a smooth ride. There is a risk you must factor in. Read HALO Dip Buyer Analyses and NBIX Dip Buyer Analyses to see how these stocks have fallen and recovered in the past.